Antimycobacterial susceptibility testing: Present practices and future trends

  • C. B. Inderlied
Current Topic: Review


Along with the worldwide renewed interest in tuberculosis, the high incidence of nontuberculous disease in HIV-infected patients and the continuing problem of disease caused by rapidly growing mycobacteria, there has been a renewed interest in mycobacterial susceptibility testing. This renewed interest stems from the needs both to provide accurate, reliable and timely susceptibility test information for the management of patients infected with these mycobacteria and to identify new and more effective antimycobacterial agents. Indeed, many new agents have already been identified and are currently used to treat these infections, but the conventional susceptibility testing methods, in many instances, have not been adequately evaluated for these new agents. Perhaps the time has come to give consideration to abandoning such time-honored practices and criteria as the proportion method, the 99 % threshold, and “critical concentrations”. New methods of susceptibility testing are in various stages of development and many of these methods have advantages and improvements over the existing methods. There is an increased understanding of the pathobiology of mycobacterial infections and an increased understanding of the pharmacokinetics of antimycobacterial agents and the mechanisms of action and resistance. This article gives an overview of the present practices and an assessment of the current needs and potential for the near future of antimycobacterial susceptibility testing.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown JW Fighting the TB dragon. Medical Laboratory Observatory 1994, 2: 31–36.Google Scholar
  2. 2.
    Davidson PD Drug resistance and the selection of therapy for tuberculosis. American Review of Respiratory Disease 1987, 136: 255–257.PubMedGoogle Scholar
  3. 3.
    Dooley SW, Jarvis WR, Martone WJ, Snider DE Multidrug-resistant tuberculosis. Annals of Internal Medicine 1992, 117: 257–259.PubMedGoogle Scholar
  4. 4.
    Iseman MD Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine 1993, 329: 784–791.CrossRefPubMedGoogle Scholar
  5. 5.
    Riley LW Drug-resistant tuberculosis. Clinical Infectious Diseases 1993, 17, Supplement 2: S442-S446.PubMedGoogle Scholar
  6. 6.
    Heifets LB, Iseman MD Determination of in vitro susceptibility of mycobacteria to ansamycin. American Review of Respiratory Disease 1985, 132: 710–711.PubMedGoogle Scholar
  7. 7.
    Heifets LB, Iseman MD, Lindholm-Levy PJ, Kanes W Determination of ansamycin MICs forMycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrobial Agents and Chemotherapy 1985, 28: 570–575.PubMedGoogle Scholar
  8. 8.
    Saito H, Sato K, Tomioka H Comparative in vitro and in vivo activity of rifabutin and rifampicin againstMycobacterium avium complex. Tubercle 1988, 69: 187–192.CrossRefPubMedGoogle Scholar
  9. 9.
    Nightingale SD, Cameron WD, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, Eron LJ, Saprti PD, Bihari B, Kaufman DL, Stern JJ, Pearce DD, Weinberg WG, LaMarca A, Siegel FP Two controlled trials of rifabutin prophylaxis againstMycobacterium avium complex infection in AIDS. New England Journal of Medicine 1993, 329: 828–833.CrossRefPubMedGoogle Scholar
  10. 10.
    Masur H Recommendations on prophylaxis and therapy for disseminatedMycobacterium avium complex disease in patients infected with the human-immunodeficiency-virus. New England Journal of Medicine 1993, 329: 898–904.CrossRefPubMedGoogle Scholar
  11. 11.
    Bermudez LE, Young LS, Inderlied CB Rifabutin and sparfloxacin but not azithromycin inhibit the binding ofMycobacterium avium complex to HT-29 intestinal mucosal cell line. Antimicrobial Agents and Chemotherapy 1994, 38: 1200–1202.PubMedGoogle Scholar
  12. 12.
    Inderlied CB, Kemper CA, Bermudez LEM TheMycobacterium avium complex. Clinical Microbiology Reviews 1993, 6: 266–310.PubMedGoogle Scholar
  13. 13.
    Farr BM, Mandell GL Rifamycins. In: Mandell GL, Douglas RG, Bennett JE (ed): Principles and practices of infectious diseases. Churchill Livingstone, New York, 1990, p. 295–303.Google Scholar
  14. 14.
    Alford RH Antimycobacterial agents. In: Mandell GL, Douglas RG, Bennett JE (ed): Principles and Practices of Infectious Diseases. Churchill Livingstone, New York, 1990, p. 350–360.Google Scholar
  15. 15.
    Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ, Böttger EC Identification of mutations in 23S rRNA gene of clarithromycin-resistantMycobacterium intracellulare. Antimicrobial Agents and Chemotherapy 1994, 38: 381–384.PubMedGoogle Scholar
  16. 16.
    Inderlied CB, Kolonski PT, Wu M, Young LS In vitro and in vivo activity of azithromycin (CP 62,993) against theMycobacterium avium complex. Journal of Infectious Diseases 1989, 159: 994–997.PubMedGoogle Scholar
  17. 17.
    Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB Azithromycin for treatment ofMycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991, 338: 1107–1109.CrossRefPubMedGoogle Scholar
  18. 18.
    Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Grosset J Activity of clarithromycin againstMycobacterium avium infection in patients with the acquired immune deficiency syndrome. American Review of Respiratory Disease 1991, 144: 564–9.PubMedGoogle Scholar
  19. 19.
    Husson RN, Ross LA, Sandelli S, Inderlied CB, Venzon D, Lewis LL, Woods L, Conville PS, Witebsky FG, Pizzo PA Orally administered clarithromycin for treatment of systemicMycobacterium avium complex infection in children with acquired immunodeficiency syndrome. Journal of Pediatrics 1994, 124: 807–814.PubMedGoogle Scholar
  20. 20.
    Casal M, Rodriguez F, Villalba R In vitro susceptibility ofMycobacterium avium to a new macrolide (RU-28965). Chemotherapy 1987, 33: 255–258.PubMedGoogle Scholar
  21. 21.
    Rastogi N, Goh KS Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrobial Agents and Chemotherapy 1992, 36: 2841–2842.PubMedGoogle Scholar
  22. 22.
    Heifets LB, Lindholm-Levy PJ, Comstock RD Clarithromycin minimal inhibitory and bactericidal concentrations againstMycobacterium avium. American Review of Respiratory Disease 1992, 145: 856–858.PubMedGoogle Scholar
  23. 23.
    Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG Lack of acidification inMycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263: 678–681.PubMedGoogle Scholar
  24. 24.
    Garcia-Rodriguez JA, Gomez Garcia AC In vitro activities of quinolones against mycobacteria. Journal of Antimicrobial Chemotherapy 1993, 32: 797–808.PubMedGoogle Scholar
  25. 25.
    Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR, Good RC The resurgence of tuberculosis: is your laboratory ready? Journal of Clinical Microbiology 1993, 31: 767–770.PubMedGoogle Scholar
  26. 26.
    Leysen DC, Haemers A, Pattyn SR Mycobacteria and the new quinolones. Antimicrobial Agents and Chemotherapy 1989, 33: 1–5.PubMedGoogle Scholar
  27. 27.
    Young LS, Berlin OG, Inderlied CB Activity of ciprofloxacin and other flourinated quinolones against mycobacteria. American Journal of Medicine 1987, 82: 23–26.CrossRefGoogle Scholar
  28. 28.
    Andriole VT Quinolones. In: Mandell GL, Douglas RG, Bennett JE (ed): Principles and practices of infectious diseases. Churchill Livingstone, New York, 1990, p. 334–345.Google Scholar
  29. 29.
    Centers for Disease Control and Prevention Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the advisory council for the elimination of tuberculosis. Morbidity and Mortality Weekly Report 1993, 42 (RR-7): 1–8.Google Scholar
  30. 30.
    Huebner RE, Good RC, Tokars JI Current practices in mycobacteriology: results of a survery of state public health laboratories. Journal of Clinical Microbiology 1993, 31: 771–775.PubMedGoogle Scholar
  31. 31.
    Woods GL, Witebsky FG Current status of mycobacterial testing in clinical laboratories. Archives of Pathology and Laboratory Medicine 1993, 117: 876–884.PubMedGoogle Scholar
  32. 32.
    Hawkins JE Drug susceptibility testing. In: Kubica GP, Wayne LG (ed): The mycobacteria: a sourcebook. Part A. Marcel Dekker, New York, 1984, p. 177–193.Google Scholar
  33. 33.
    Wayne LG, Krasnow I Preparation of tuberculosis susceptibility testing mediums by means of impregnated disks. American Journal of Clinical Pathology 1966, 45: 769–771.PubMedGoogle Scholar
  34. 34.
    Kent PT, Kubica GP Public health mycobacteriology — A guide for the level III laboratory. Centers for Disease Control, Atlanta, GA, 1985, p. 207.Google Scholar
  35. 35.
    Hacek D Modified proportion agar dilution test for slowly growing mycobacteria. In: Isenberg HD, Hindler JA (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC, 1992, p. 5.13.1–5.13.15.Google Scholar
  36. 36.
    Inderlied CB Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance, and assays for activity in biological fluids. In: Lorian V (ed): Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, 1991, p. 134–197.Google Scholar
  37. 37.
    National Committee on Clinical Laboratory Standards: Antimycobacterial susceptibility testing. Proposed standard M24-P NCCLS, Villanova, PA, 1990, p. 21.Google Scholar
  38. 38.
    Guthertz LS, Griffith ME, Ford EG, Janda JM/Midura TF Quality control or individual components used in Middlebrook 7H10 medium for mycobacterial susceptibility testing. Journal of Clinical Microbiology 1988, 26: 2338–2342.PubMedGoogle Scholar
  39. 39.
    Griffith ME, Bodily HL Stability of antimycobacterial drugs in susceptibility testing. Antimicrobial Agents and Chemotherapy 1992, 36: 2398–2402.PubMedGoogle Scholar
  40. 40.
    Rastogi N, Frehel C, Ryter A, Ohayon H, Lesourd M, David HL Multiple drug resistance inMycobacterium avium: is the wall architecture responsible for the exclusion of antimicrobial agents? Antimicrobial Agents and Chemotherapy 1981, 20: 666–677.PubMedGoogle Scholar
  41. 41.
    Mizuguchi Y, Ogawa M, Udou T Morphological changes induced by β-lactam antibiotics inMycobacterium avium-intracellulare complex. Antimicrobial Agents and Chemotherapy 1985, 27: 541–547.PubMedGoogle Scholar
  42. 42.
    Crawford JT, Falkinham JO Plasmids of theMycobacterium avium complex. In: McFadden J (ed): Molecular biology of the mycobacteria. Surrey University Press, London, 1990, p. 97–119.Google Scholar
  43. 43.
    Crawford JT, Bates JH Analysis of plasmids inMycobacterium avium-intracellulare isolates from persons with acquired immunodeficiency syndrome. American Review of Respiratory Disease 1986, 134: 659–661.PubMedGoogle Scholar
  44. 44.
    Morris SL, Rouse DA, Malik A, Chaparas SD, Witebsky FG Characterization of plasmids extracted from AIDS-associatedMycobacterium avium isolates. Tubercle 1990, 71: 181–185.CrossRefPubMedGoogle Scholar
  45. 45.
    Jucker MT, Falkinham JO Epidemiology of infection by nontuberculous mycobacteria IX. Evidence for two DNA homology groups among small plasmids inMycobacterium avium, Mycobacterium intracellulare, andMycobacterium scrofulaceum. American Review of Respiratory Disease 1990, 142: 858–862.PubMedGoogle Scholar
  46. 46.
    Franzblau SG, Takeda T, Nahamura M Mycobacterial plasmids: screening and possible relationship to antibiotic resistance inMycobacterium avium-Mycobacterium intracellulare. Microbiology and Immunology 1986, 30: 903–907.PubMedGoogle Scholar
  47. 47.
    Mizuguchi Y, Fukunaga M, Taniguchi H Plasmid deoxyribonucleic acid and translucent-to-opaque variation inMycobacterium intracellulare 103. Journal of Bacteriology 1981, 146: 656–659.PubMedGoogle Scholar
  48. 48.
    Arbeit RD, Slutsky A, Barber TW, Maslow JN, Niemezyk S, Falkinham JO, O'Conner GT, Fordham von Reyn C Genetic diversity among strains ofMycobacterium avium causing monoclonal and polyclonal bacteremia in patients with AIDS. Journal of Infectious Diseases 1993, 167: 1384–1390.PubMedGoogle Scholar
  49. 49.
    Heifets L MIC as a quantitative measurement of the susceptibility ofMycobacterium avium strains to seven antituberculosis drugs. Antimicrobial Agents and Chemotherapy 1988, 32: 1131–1136.PubMedGoogle Scholar
  50. 50.
    Inderlied CB, Young LS, Yamada JK Determination of in vitro susceptibility ofMycobacterium avium complex isolates to antimicrobial agents by various methods. Antimicrobial Agents and Chemotherapy 1987, 31: 1697–1702.PubMedGoogle Scholar
  51. 51.
    Tsukamura M, Miyachi T Correlations among naturally occurring resistances to antituberculosis drugs inMycobacterium avium complex strains. American Review of Respiratory Disease 1989, 139: 1033–5.PubMedGoogle Scholar
  52. 52.
    Good RC Opportunistic pathogens in the genusMycobacterium. Annals Review of Microbiology 1985, 39: 347–369.CrossRefGoogle Scholar
  53. 53.
    Heifets L, Mor N, Vanderkolk J Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrobial Agents and Chemotherapy 1993, 37: 2364–2370.PubMedGoogle Scholar
  54. 54.
    Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, Lindholm-Levy PJ, Pearson N Rapid broth macrodilution method for determination of MICs forMycobacterium avium isolates. Journal of Clinical Microbiology 1993, 31: 2332–2338.PubMedGoogle Scholar
  55. 55.
    Yajko DM, Nassos PS, Hadley WK Broth microdilution testing of susceptibilities to 30 antimicrobial agents ofMycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrobial Agents and Chemotherapy 1987, 31: 1579–1584.PubMedGoogle Scholar
  56. 56.
    Siddiqi SH Radiometric (Bactec) tests for slowly growing mycobacteria. In: Isenberg HD, Hindler JA (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC, 1992, p. 5.14.1–5.14.25.Google Scholar
  57. 57.
    Heifets LB, Iseman MD Choice of antimicrobial agents forMycobacterium avium disease based on quantitative tests of drug susceptibility. New Eng. Journal of Medicine 1990, 323: 419–420.Google Scholar
  58. 58.
    Woods GL, Washington JA Mycobacteria other thanMycobacterium tuberculosis: review of microbiologic and clinical aspects. Review of Infectious Diseases 1987, 9: 275–294.Google Scholar
  59. 59.
    Rastogi N, Goh KS, Guillou N, Labrousse V Spectrum of drugs against atypical mycobacteria: how valid is the current practice of susceptibility testing and the choice of drugs? Zentralblatt für Bakteriologie 1992, 277: 474–484.Google Scholar
  60. 60.
    Davidson PT The diagnosis and management of disease caused byMycobacterium avium complex,Mycobacterium kansasii, and other mycobacteria. In: Snider DE (ed): Clinics in chest medicine. Saunders, Philadelphia, 1989, p. 431–443.Google Scholar
  61. 61.
    Bruckner DA, Colonna P Nomenclature for aerobic and facultative bacteria. Clinical Infectious Diseases 1993, 16: 598–605.PubMedGoogle Scholar
  62. 62.
    Wallace RJ, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS Spectrum of disease due to rapidly growing mycobacteria. Review of Infectious Diseases 1983, 4: 326–331.Google Scholar
  63. 63.
    McFarland EJ, Kuritzkes DR Clinical features and treatment of infection due toMycobacterium fortuitum/chelonae complex. In: Remington JS, Swartz MN (ed): Current clinical topics in infectious diseases. Blackwell Scientific Publications, Boston, 1993, p. 188–202.Google Scholar
  64. 64.
    Wallace RJ The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria,Mycobacterium fortuitum andMycobacterium chelonae. Clinics in Chest Medicine 1989, 10: 419–429.PubMedGoogle Scholar
  65. 65.
    Hawkins JE, Wallace RJ, Brown BA Antibacterial susceptibility tests: mycobacteria. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1991, p. 1138–1152.Google Scholar
  66. 66.
    Brown BA, Swenson JM, Wallace RJ Broth microdilution test for rapidly growing mycobacteria. In: Isenberg HD, Hindler JA (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC, 1992, p. 5.11.1–5.11.10.Google Scholar
  67. 67.
    Brown BA, Swenson JM, Wallace RJ Agar disk elution test for rapidly growing mycobacteria. In: Isenberg HD, Hindler JA (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC, 1992, p. 5.10.1–5.10.11.Google Scholar
  68. 68.
    Zhang Y, Heym B, Allen B, Young D, Cole S The catalase-peroxidase gene and isoniazid resistance ofMycobacterium tuberculosis. Nature 1992, 358: 591–593.CrossRefPubMedGoogle Scholar
  69. 69.
    Heym B, Cole ST Isolation and characterization of isoniazid-resistant mutants ofMycobacterium smegmatis andMycobacterium aurum. Research in Microbiology 1992, 143: 721–730.CrossRefPubMedGoogle Scholar
  70. 70.
    Heym B, Zhang Y, Poulet S, Young D, Cole ST Characterization of thekatG gene encoding a catalase-peroxidase required for isoniazid susceptibility ofMycobacterium tuberculosis. Journal of Bacteriology 1993, 175: 4255–4259.PubMedGoogle Scholar
  71. 71.
    Rosner J Susceptibilities ofoxyR regulon mutants ofEscherichia coli andSalmonella typhimurium to isoniazid. Antimicrobial Agents and Chemotherapy 1993, 37: 2251–2253.PubMedGoogle Scholar
  72. 72.
    Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR ihA, a gene encoding a target for isonazid and ethionamide inMycobacterium tuberculosis. Science 1994, 263: 227–230.PubMedGoogle Scholar
  73. 73.
    Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T Detection of rifampin-resistance mutations inMycobacterium tuberculosis. Lancet 1993, 341: 647–650.CrossRefPubMedGoogle Scholar
  74. 74.
    Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T Direct, automated detection of rifampin-resistantMycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrobial Agents and Chemotherapy 1993, 37: 2054–2058.PubMedGoogle Scholar
  75. 75.
    Honore N, Cole ST Molecular basis of rifampin resistance inMycobacterium leprae. Antimicrobial Agents and Chemotherapy 1993, 37: 414–418.PubMedGoogle Scholar
  76. 76.
    Finken M, Kirschner P, Meier A, Wrede A, Böttger EC Molecular basis of streptomycin resistance inMycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Molecular Microbiology 1993, 9: 1239–1246.PubMedGoogle Scholar
  77. 77.
    Nair J, Rouse DA, Bai GH, Morris SL TherpsL gene and streptomycin resistance in single and multiple drug-resistant strains ofMycobacterium tuberculosis. Molecular Microbiology 1993, 10: 521–527.PubMedGoogle Scholar
  78. 78.
    Meier A, Kirschner P, Bange FC, Vogel U, Böttger EC Genetic alterations in streptomycin-resistantMycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrobial Agents and Chemotherapy 1994, 38: 228–233.PubMedGoogle Scholar
  79. 79.
    Daley CL, Small PM, Schecter GF, Schollnik GK, McAdam RA, Jacobs WR, Hopewell PC An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction fragment length polymorphisms. New England Journal of Medicine 1992, 326: 231–235.PubMedGoogle Scholar
  80. 80.
    Hermans PWM, van Soolingen D, Dale JW, Schuitema R, McAdam A, Catty D, van Embden JDA Insertion element IS986 fromMycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis. Journal of Clinical Microbiology 1990, 28: 2051–2058.PubMedGoogle Scholar
  81. 81.
    Mazurek GH, Hartman S, Zhang Y, Brown BA, Hector JSR, Murphy D Wallace RJ Large DNA restriction fragment polymorphism in theMycobacterium avium-intracellulare complex: a potential epidemiologic tool. Journal of Clinical Microbiology 1993, 31: 390–394.PubMedGoogle Scholar
  82. 82.
    Zhang YS, Mazurek GH, Cave MD, Eisenach KD, Pang YJ, Murphy DT, Wallace RJ DNA polymorphisms in strains ofMycobacterium tuberculosis analyzed by pulsed field gel electrophoresis — a tool for epidemiology. Journal of Clinical Microbiology 1993, 30: 1551–1556.Google Scholar
  83. 83.
    Eisenach KD, Crawford JT, Bates JH Repetitive DNA sequences as probes forMycobacterium tuberculosis. Journal of Clinical Microbiology 1988, 26: 2240–2245.PubMedGoogle Scholar
  84. 84.
    Van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Schinnick TM, Small PM Strain identification ofMycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. Journal of Clinical Microbiology 1993, 31: 406–409.PubMedGoogle Scholar
  85. 85.
    Plikaytis BB, Crawford JT, Woodley CL, Butler WR, Eisenach KD, Cave MD Rapid, amplification-based fingerprinting ofMycobacterium tuberculosis. Journal of General Microbiology 1993, 139: 1537–1542.PubMedGoogle Scholar
  86. 86.
    Jacobs WR, Barletta RG, Udani R, Chan J, Kalkut G, Sosne G, Kieser T, Sarkis GJ, Hatfull GF, Bloom BR Rapid assessment of drug susceptibilities ofMycobacterium tuberculosis by means of luciferase reporter phages. Science 1993, 260: 819–822.PubMedGoogle Scholar
  87. 87.
    Cooksey RC, Crawford JT, Jacobs WR, Shinnick TM A rapid method for screening antimicrobial agents for activities against a strain ofMycobacterium tuberculosis expressing firefly luciferase. Antimicrobial Agents and Chemotherapy 1993, 37: 1348–1352.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1994

Authors and Affiliations

  • C. B. Inderlied
    • 1
    • 2
  1. 1.Department of PathologyUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of Pathology and Laboratory MedicineChildren's HospitalLos AngelesUSA

Personalised recommendations